
    
      The duration of the study period is up to 87 weeks, including a Screening Period consisting
      of a Screening phase of up to 2 weeks and a 2 week single blind Run-in phase, a 26 week
      double-blind Core Treatment Period, a 53-week double-blind Extension Period, a 4 week post
      treatment Follow-up period to collect safety information.
    
  